Meet the team behind Parexel's advancing precision oncology report at #ESMO24. Our experts will be in Barcelona from Sept. 13 - 17 sharing and learning from the industry's best minds on the latest innovations and strategies driving cancer research towards improved patient outcomes. This latest report focuses on oncology treatments that offer the promise of maximum benefits with minimum off-target effects and are universally accessible. Learn how our team is working to realize the vision of precision oncology by solving one challenge at a time: https://lnkd.in/dk3iVwhw To find out how Parexel can apply innovative, proven solutions to your oncology trials, schedule a meeting or visit us at booth 415: https://lnkd.in/dm6-6VZf #PrecisionOncology #Oncology #PatientsFirst #ClinicalResearch Gwyn Bebb Angela Qu, MD, PHD Sinan B. Sarac (MD, MSc, PhD) Pengfei Song Angela Hirst
About us
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.
- Website
-
http://www.parexel.com
External link for Parexel
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Specialties
- Regulatory and product development consulting, early phase clinical research, phase II-III clinical research, late phase clinical research, eClinical solutions, patient and site recruitment, medical device consulting, clinical research organization, pharmacovigilance, biotechnology, biotech, and market access
Locations
-
Primary
2520 Meridian Pkwy
Durham, North Carolina 27713, US
Employees at Parexel
Updates
-
"I believe that the key #AI milestones will involve achieving community and regulatory acceptance of these innovative methods - and we’re absolutely seeing progress in this area." - Andy Wilson, Head of Innovative RWD Analytics at Parexel In the latest from our #AIandMe series reviewing how AI is reshaping everyday work in clinical research, Andy shared his and other's excitement around AI capabilities, specifically causal methods and advancements, while noting some occasional misunderstandings and limitations. "In the near term, AI and ML are being used to identify eligible patients, expedite literature reviews, and improve trial efficiency. In the longer term, AI and ML could be used to integrate real-world data into trials, reduce trial duration, and minimize the number of patients allocated to control arms." The latter is where Andy is focused in leveraging AI at the service of established causal methods. "One of the emerging frontiers in using methods like targeted maximum likelihood estimation (TMLE) methods is the ability to estimate effects in increasingly complex real-world scenarios." Andy shared how generative models can be used to create "what if" scenarios that help us better understand and anticipate patient outcomes as an extension of established data methods, while eliminating privacy and security concerns. Concluding with a quote from Pablo Picasso, "Computers are useless; they only give you answers." Andy finds this sentiment reflects a broader issue in our expectations of AI when we seek solutions without clearly defining the problem it should address. He's excited by the movement toward more 'collaborative learning' where data engineers can work in lockstep with the clinical experts implementing findings, rather than siloed from each other. Tag Andy below if you have questions or comments from our recent conversation and stay tuned for more looks into how AI is reshaping everyday work for our Parexel teams! #ArtificialIntelligence #MachineLearning #GenerativeAI #TMLE #ClinicalResearch #DrugDevelopment
-
Parexel today announced the strengthening of its Real World Research (RWR) offering, bringing together the company’s Scientific Data Organization (SDO) and Real World Evidence (RWE) capabilities to better meet growing customer needs. This strategic alignment will more effectively leverage Parexel’s novel study design and methodology for primary site-based and secondary data/non-site-based real world research to offer customers best-in-class evidence generation solutions. To lead this growing area of focus, Parexel has appointed Mike D'Ambrosio as Senior Vice President, Global Head, Real World Research. Mike will lead strategic initiatives to enhance customer engagement and delivery across Real World Data (RWD) and RWE services, helping to foster a deeper understanding of patient experiences and outcomes to ensure safety and efficacy in the drug development process. Read the release: https://lnkd.in/dZVByR2X #realworlddata #RWD #realworldevidence #RWE
-
“Artificial intelligence (AI) solutions can streamline and enhance the use of real-world data (RWD) to generate real-world evidence (RWE)” In this edition of the New Medicines, Novel Insights newsletter, Parexel RWE experts Jacqueline Vanderpuye-Orgle and Matthew Gordon review the potential AI offers in streamlining clinical datasets that can fill evidence gaps and address research questions faster, ultimately providing patients access to much needed therapies. RWD can be leveraged to accelerate clinical development and support a wide variety of commercial objectives — but only if researchers have meaningful ways to harness the potential power of massive and often unstructured datasets. Learn about Parexel’s promising results using machine-learned Bayesian networks, a form of predictive modeling, and one approach in a suite of methods to make AI more transparent. Read the full article and make sure you subscribe to get the latest #NovelInsights each week! #AI #RWD #RWE #ArtificialIntelligence
-
Parexel colleagues around the world gathered over the summer to share meals, enjoy time together and make memories. ☀️ 🍗The team at our North American Distribution Center in Quakertown, PA, gathered to grill up some BBQ! 🎓Japan's Leadership Team hosted welcome dinners in Tokyo and Osaka for recent grads who joined Parexel. 🏃♀️In Poland, colleagues continued their annual tradition of running an ekiden long-distance relay race. 🎳Our Mexico colleagues took over a bowling alley! 🥭Our India colleagues celebrated different cuisines and flavors with food festivals and traditional feasts. Click through our gallery of summer events around the world and tag someone you know in the comments! 🌍 #LifeAtParexel
-
-
-
-
-
+6
-
-
Leading up to #LightTheNight with The Leukemia & Lymphoma Society this October, we’re sharing stories from colleagues impacted by #bloodcancer. Parexel’s Bhavani Pemmaraju graciously opened up about her family’s experience after her father-in-law’s devastating diagnosis and passing. Her story is a testament to the strength of family ties and the impact of community support in the fight against blood cancer. Click through to read 👉 #LLS #multiplemyeloma
-
Transforming lives is possible when inflammation and immunology trials are designed with precision and compassion. 💡 Our dedicated team works tirelessly to accelerate innovative treatments for patients like Tina. By focusing on the right indications, pinpointing ideal trial locations and complying with global regulations, we facilitate safe and efficient market access for your therapies. 🧑🤝🧑 We prioritize the patient experience by actively listening to patients, caregivers and healthcare professionals, ensuring their perspectives are integrated throughout the trial process. Discover how our expertise in inflammation and immunology can help you make a difference in patient lives by visiting: https://lnkd.in/dyvh9J2W #patientsfirst
-
We are thrilled to welcome Dr. Benedikt Egersdoerfer to Parexel! As SVP and Head of Global Data Operations (GDO), Dr. Egersdörfer brings more than 25 years of pharmaceutical and CRO industry experience to the company. His passion and expertise in data acquisition, integration, analysis and reporting will be invaluable as we work to leverage innovative data collection methods to reduce the burden on patients and sites. Find out how Dr. Egersdörfer is planning to work #WithHeart for patients 👉 https://lnkd.in/dDshXuWf
-
“Increasing the probability of success in Phase 2 depends on meticulous planning and a solid risk management strategy.” In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with varying subject matter experts from Parexel on their recommended steps to take in early phase development to mitigate avoidable clinical trial risks. Though there is no simple solution to preventing the unknowns in clinical development, avoiding missteps through strategic planning and foresight can put your company in the best position for success. Read the full article and subscribe for the latest #NovelInsights #ParexelBiotech #EarlyPhase #DrugDevelopment #ClinicalTrials
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Parexel on LinkedIn
-
🚀 Two decades of excellence: A clinical operations leader's journey at Parexel 🚀 Cristina DiRenzo's remarkable 20-year career at Parexel is a testament to the power of professional growth, mentorship and dedication. At Parexel, we nurture talent and foster success through: 🔹 A collaborative team environment 🔹 Commitment to delivering high-quality clinical trials to benefit patients 🔹 Diverse career paths tailored to your goals 🔹 Continuous learning and development opportunities Are you passionate about advancing healthcare through clinical research? Join our team and chart your course to success at Parexel! https://insde.co/n15o #ParexelCareers #ClinicalTrials #CareerGrowth #WithHeart
-